Literature DB >> 16903993

Managing meningococcal disease in the United States: Hospital case characteristics and costs by age.

Judith A O'Brien1, J Jaime Caro, Denis Getsios.   

Abstract

OBJECTIVE: Meningococcal disease occurs worldwide. Approximately 1400 to 2800 cases are reported in the United States annually. The goal of this analysis was to examine hospitalized cases of meningitis and meningococcemia to identify case characteristics, resource use, and inpatient care costs.
METHODS: International Classification of Diseases-9th Revision-Clinical Modification diagnosis codes 036.0-036.9 were used to identify cases from roughly 1000 hospitals in four all payer state discharge databases. Multiyear data (1999-2001) were examined to identify demographics, admission month, health service utilization, and hospital costs by age group: infant (<1 years), children (1-10 years), adolescent (11-17 years), young adult (18-22 years), adults (23-49 years), and adults (> or =50 years). Cost estimates include accommodations, ancillary and physician services, reported in 2003 US dollars.
RESULTS: Of 1654 cases of meningococcal disease identified, meningococcemia was coded for 51%. Adults accounted for 33% of the cases. The highest rate of admissions occurred from January through March and 62% were admitted via the Emergency Department. Inpatient case fatality rate was 6.4%; 71% of those who died had meningococcemia. The mean length of stay was 9 days. Of survivors, 91% were discharged home (1% with intravenous medications and 11% with other home health-care services) while 7% required further subacute inpatient care. The average cost per hospitalization was estimated at 23,294 dollars per patient. Infants had the lowest average cost per stay (16,793 dollars) and adolescents had the highest (28,202 dollars).
CONCLUSIONS: The presence of meningococcemia results in a greater death rate, longer length of stay, and increased care costs. Meningococcal disease has substantial economic, as well as profound clinical consequences for patients of all ages.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16903993     DOI: 10.1111/j.1524-4733.2006.00113.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  7 in total

1.  Bacterial meningitis in older adults.

Authors:  Diedre Hofinger; Larry E Davis
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

2.  Costs of Invasive Meningococcal Disease: A Global Systematic Review.

Authors:  Bing Wang; Renee Santoreneos; Hossein Afzali; Lynne Giles; Helen Marshall
Journal:  Pharmacoeconomics       Date:  2018-10       Impact factor: 4.981

Review 3.  The changing epidemiology of meningococcal disease in North America 1945-2010.

Authors:  Carmen Baccarini; Andrew Ternouth; Heather Wieffer; Andrew Vyse
Journal:  Hum Vaccin Immunother       Date:  2012-10-29       Impact factor: 3.452

4.  Outcomes and Health Care Resource Utilization of Adult Bacterial Meningitis in the United States.

Authors:  Musa Kiyani; Sarah E Hodges; Syed M Adil; Lefko T Charalambous; Beiyu Liu; Hui-Jie Lee; Beth Parente; John R Perfect; Shivanand P Lad
Journal:  Neurol Clin Pract       Date:  2021-04

5.  Healthcare Resource Utilization and Cost of Invasive Meningococcal Disease in Ontario, Canada.

Authors:  Emmanouil Rampakakis; Julie Vaillancourt; Sara Mursleen; John S Sampalis
Journal:  Pediatr Infect Dis J       Date:  2019-03       Impact factor: 2.129

6.  Clinical and economic burden of invasive meningococcal disease: Evidence from a large German claims database.

Authors:  Liping Huang; Olivia Denise Heuer; Sabrina Janßen; Dennis Häckl; Niklas Schmedt
Journal:  PLoS One       Date:  2020-01-28       Impact factor: 3.240

7.  Care pathways in invasive meningococcal disease: a retrospective analysis of the French national public health insurance database.

Authors:  Catherine Weil-Olivier; Muhamed-Kheir Taha; Stéphane Bouée; Corinne Emery; Véronique Loncle-Provot; Gaëlle Nachbaur; Ekkehard Beck; Céline Pribil
Journal:  Hum Vaccin Immunother       Date:  2022-02-22       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.